Earnings History Data for Fulcrum Therapeutics, Inc. (FULC) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
13-11-2024	PM		FULC	Fulcrum Therapeutics, Inc.	227.14	-0.35	-0.40	-0.39	Fulcrum Therapeutics GAAP EPS of -$0.35 beats by $0.05 [11/13/2024 7:21 AM]	3.57	-0.07 (-1.95%)	3.86	0.22 (6.04%)	2.87 - 13.70	719,245	790,000	31,107
Fulcrum Therapeutics GAAP EPS of -$0.35 beats by $0.05 [11/13/2024 7:21 AM] Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 [2024-11-13 07:00AM] Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference [Nov-12-24 04:05PM]
31-07-2024	PM		FULC	Fulcrum Therapeutics, Inc.	523.96	0.87	-0.06	-0.38	Fulcrum Therapeutics GAAP EPS of $0.87 beats by $0.88, revenue of $80M beats by $38.89M [7/31/2024 7:18 AM]	9.25	0.84 (9.99%)	8.96	0.55 (6.54%)	3.14 - 13.70	1,273,702	460,000	12,913
Fulcrum Therapeutics Q2 2024 Earnings Preview [7/30/2024 12:34 PM] Fulcrum Therapeutics GAAP EPS of $0.87 beats by $0.88, revenue of $80M beats by $38.89M [7/31/2024 7:18 AM]
13-05-2024	PM		FULC	Fulcrum Therapeutics, Inc.	464.51	-0.43	-0.44	-0.41	Fulcrum Therapeutics GAAP EPS of -$0.43 in-line [5/13/2024 7:22 AM]	7.40	-0.07 (-0.94%)	8.35	0.88 (11.78%)	2.65 - 13.70	1,710,608	290,000	180,247
Fulcrum Therapeutics GAAP EPS of -$0.43 in-line [5/13/2024 7:22 AM] Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate [5/13/2024 10:09 AM]
27-02-2024	PM		FULC	Fulcrum Therapeutics, Inc.	593.50	-0.40	-0.44	-0.50	Fulcrum Therapeutics GAAP EPS of -$0.40 beats by $0.04, revenue of $0.87M beats by $0.48M [2/27/2024 7:10 AM]	10.25	0.52 (5.34%)	9.90	0.17 (1.75%)	2.25 - 10.50	1,384,993	580,000	1,220
Fulcrum Therapeutics Q4 2023 Earnings Preview [2/26/2024 12:41 PM] Fulcrum Therapeutics GAAP EPS of -$0.40 beats by $0.04, revenue of $0.87M beats by $0.48M [2/27/2024 7:10 AM]
07-11-2023	PM		FULC	Fulcrum Therapeutics, Inc.	240.49	-0.39	-0.44	-0.50	Fulcrum Therapeutics GAAP EPS of -$0.39 beats by $0.04, revenue of $0.76M misses by $0.29M [11/7/2023 7:16 AM]	4.30	0.71 (19.78%)	3.66	0.07 (1.99%)	2.25 - 15.00	1,150,012	410,000	1,317
Fulcrum Therapeutics GAAP EPS of -$0.39 beats by $0.04, revenue of $0.76M misses by $0.29M [11/7/2023 7:16 AM]
03-08-2023	PM		FULC	Fulcrum Therapeutics, Inc.	229.13	-0.38	-0.44	-0.83	Fulcrum Therapeutics GAAP EPS of -$0.38 beats by $0.06, revenue of $0.9M misses by $0.06M [8/3/2023 10:18 AM]	3.85	0.03 (0.79%)	4.10	0.28 (7.33%)	2.25 - 15.00	709,290	560,000	128
Fulcrum Therapeutics appoints Alan A. Musso as chief financial office [8/3/2023 9:25 AM] Fulcrum Therapeutics GAAP EPS of -$0.38 beats by $0.06, revenue of $0.9M misses by $0.06M [8/3/2023 10:18 AM]
15-05-2023	PM	7:15 AM ET (May 15)	FULC	Fulcrum Therapeutics, Inc.	196.39	-0.41	-0.47	-0.64	Fulcrum Therapeutics GAAP EPS of -$0.41 beats by $0.05, revenue of $0.3M misses by $0.68M [5/15/2023 7:12 AM]	3.63	0.36 (10.93%)	3.42	0.15 (4.59%)	2.25 - 15.00	829,670	770,000	3,086
Fulcrum Therapeutics GAAP EPS of -$0.41 beats by $0.05, revenue of $0.3M misses by $0.68M [5/15/2023 7:12 AM] Fulcrum Therapeutics appoints new executive chief [5/15/2023 7:33 AM]
09-03-2023	PM	7:15 AM ET (Mar 9)	FULC	Fulcrum Therapeutics, Inc.	792.42	-0.50	-0.49	-0.58	Fulcrum Therapeutics GAAP EPS of -$0.50 misses by $0.01, revenue of $0.7M misses by $1.19M [3/9/2023 7:12 AM]	4.82	-1.44 (-23.00%)	5.23	-1.03 (-16.45%)	3.21 - 24.79	3,133,035	2,120,000	38,160
Fulcrum Therapeutics GAAP EPS of -$0.50 misses by $0.01, revenue of $0.7M misses by $1.19M [3/9/2023 7:12 AM] Fulcrum plunges 23% after Q4 update as medical chief departs [3/9/2023 2:07 PM]
08-11-2022	PM	7:00 AM ET (Nov 8)	FULC	Fulcrum Therapeutics, Inc.	317.44	-0.50	-0.62	-0.57	Fulcrum Therapeutics GAAP EPS of -$0.51 beats by $0.11, revenue of $1.18M misses by $1.36M [11/8/2022 7:20 AM]	6.50	0.89 (15.86%)	0.0	0.0 (0.00%)	3.21 - 24.79	463,919	340,000	0
Fulcrum Therapeutics names new chief medical officer, chief scientific officer [11/7/2022 5:38 PM] Fulcrum Therapeutics GAAP EPS of -$0.51 beats by $0.11, revenue of $1.18M misses by $1.36M [11/8/2022 7:20 AM] Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer [Nov-07-22 05:00PM]
11-08-2022	PM	7:00 AM ET (Aug 11)	FULC	Fulcrum Therapeutics, Inc.	229.16	-0.83	-0.66	-0.60	Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M [8/11/2022 7:23 AM]	7.54	-0.22 (-2.84%)	7.38	-0.38 (-4.90%)	3.21 - 33.10	514,052	540,000	571
Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M [8/11/2022 7:23 AM] Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update [Aug-11-22 07:00AM]
09-05-2022	PM	7:00 AM ET (May 9)	FULC	Fulcrum Therapeutics, Inc.	359.61	-0.64	-0.63	-0.54	Fulcrum Therapeutics GAAP EPS of -$0.64 misses by $0.02, revenue of $2.6M misses by $1.34M [5/9/2022 7:05 AM]	7.64	-0.99 (-11.47%)	8.22	-0.41 (-4.75%)	6.85 - 33.10	1,123,082	720,000	200
Fulcrum Therapeutics GAAP EPS of -$0.64 misses by $0.02, revenue of $2.6M misses by $1.34M [5/9/2022 7:05 AM] Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [May-06-22 08:00AM] Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results [May-09-22 07:00AM] Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates [May-09-22 08:25AM] Fulcrum Therapeutics, Inc. (FULC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? [May-09-22 09:55AM]
03-03-2022	PM	7:00 AM ET (Mar 3)	FULC	Fulcrum Therapeutics, Inc.	446.04	-0.58	-0.65	-0.64	Fulcrum Therapeutics GAAP EPS of -$0.58 beats by $0.09, revenue of $5.06M beats by $1.54M [3/3/2022 7:14 AM]	11.07	-0.03 (-0.27%)	11.06	-0.04 (-0.36%)	6.85 - 33.10	385,380	290,000	1,602,264
Fulcrum Therapeutics GAAP EPS of -$0.58 beats by $0.09, revenue of $5.06M beats by $1.54M [3/3/2022 7:14 AM] Fulcrum plans phase 3 trial of losmapimod to treat rare muscle disorder [3/3/2022 8:39 AM] Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results [Mar-03-22 07:01AM] Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) [Mar-03-22 07:00AM] Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates [Mar-03-22 08:35AM] Fulcrum Therapeutics To Start Late-Stage Losmapimod Trial In Rare Muscle Wasting Disorder [Mar-03-22 11:24AM]
04-11-2021	PM	7:00 AM ET (Nov 4)	FULC	Fulcrum Therapeutics, Inc.	886.97	-0.57	-0.64	-0.70	Fulcrum Therapeutics beats on revenue [11/4/2021 7:05 AM]	21.15	0.67 (3.27%)	21.15	0.0 (0.00%)	6.85 - 33.10	1,021,981	370,000	4,760
Fulcrum Therapeutics beats on revenue [11/4/2021 7:05 AM] Fulcrum Therapeutics to Participate in Upcoming November Investor Conferences [Nov-03-21 07:00AM] Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results [Nov-04-21 07:00AM] Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates [Nov-04-21 08:35AM]
10-08-2021	PM	7:00 AM ET (Aug 10)	FULC	Fulcrum Therapeutics, Inc.	264.70	-0.60	-0.65	-0.66	Fulcrum Therapeutics beats on revenue [8/10/2021 7:08 AM]	18.77	10.44 (125.33%)	13.19	4.86 (58.34%)	6.85 - 22.09	98,865,897	230,000	4,238,718
Fulcrum Therapeutics beats on revenue [8/10/2021 7:08 AM] Fulcrum Therapeutics surges on early-stage results for sickle cell disease therapy [8/10/2021 7:35 AM] Fulcrum Therapeutics more than doubles as Stifel raises price target [8/10/2021 3:45 PM] Fulcrum Therapeutics shares under pressure after $100M capital raise [8/10/2021 4:28 PM] Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results [Aug-10-21 07:01AM] Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease [Aug-10-21 07:00AM] Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates [Aug-10-21 09:05AM] Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today [Aug-10-21 10:56AM] Fulcrum Stock Nearly Triples Why Shares Went Gangbusters On Sickle Cell Drug [Aug-10-21 12:45PM] Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock [Aug-10-21 04:24PM]
06-05-2021	PM	7:00 AM ET (May 6)	FULC	Fulcrum Therapeutics, Inc.	371.48	-0.54	-0.66	-0.81	Fulcrum Therapeutics beats on revenue [5/6/2021 7:12 AM]	10.58	0.51 (5.06%)	10.20	0.13 (1.29%)	7.01 - 22.39	83,881	90,000	2,251
Fulcrum Therapeutics beats on revenue [5/6/2021 7:12 AM] Fulcrum Therapeutics has a new medical chief [5/6/2021 8:15 AM] Fulcrum Therapeutics Inc to Host Earnings Call [May-06-21 06:15AM] Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results [May-06-21 07:01AM] Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates [May-06-21 08:55AM] Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer [May-06-21 07:00AM]
04-03-2021	PM	7:00 AM ET (Mar 4)	FULC	Fulcrum Therapeutics, Inc.	402.91	-0.64	-0.72	-0.71	Fulcrum Therapeutics EPS beats by $0.08, beats on revenue [3/4/2021 7:11 AM]	12.52	-2.07 (-14.19%)	14.59	0.0 (0.00%)	7.01 - 22.39	197,677	88,395	519
Fulcrum Therapeutics EPS beats by $0.08, beats on revenue [3/4/2021 7:11 AM] Fulcrum Therapeutics halts COVID-19 trial; names new CEO [3/4/2021 11:48 AM] Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates [Mar-04-21 08:25AM]
10-11-2020	PM	7:00 AM ET (Nov 10)	FULC	Fulcrum Therapeutics, Inc.	320.65	-0.70	-0.66	-0.97	Fulcrum Therapeutics EPS misses by $0.03, beats on revenue [11/10/2020 7:08 AM]	10.88	0.06 (0.55%)	10.82	0.0 (0.00%)	6.66 - 22.96	135,220	213,932	504

11-08-2020	PM	7:00 AM ET (Aug 11)	FULC	Fulcrum Therapeutics, Inc.	469.41	-0.66	-0.80	-9.21	Fulcrum Therapeutics EPS beats by $0.13 [8/11/2020 7:03 AM]	9.39	-7.73 (-45.15%)	11.70	-5.42 (-31.66%)	4.37 - 22.96	1,127,330	31,509	14,472

13-05-2020	PM	7:00 AM ET (May 13)	FULC	Fulcrum Therapeutics, Inc.	410.02	-0.81	-0.75	0.00	Fulcrum Therapeutics EPS misses by $0.06 [5/13/2020 7:04 AM]	16.48	1.57 (10.53%)	0.0	0.0 (0.00%)	4.37 - 22.96	349,158	76,281	0